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The binding of Cbl-interacting protein of 85kDa (CIN85) to c-Cbl is important to endocytosis and degradation of epidermal growth factor
receptor (EGFR). The proline–arginine motif PXXXPR in c-Cbl and SH3 domains of CIN85 are essential to this interaction. Here, we
demonstrated that SH3KBP1-binding protein 1 (SHKBP1), which also contains two PXXXPR motifs, constitutively bound to SH3 domains
of CIN85. Importantly, the binding of SHKBP1 prevented the interaction of CIN85 with c-Cbl and inhibited the translocation of CIN85 to
EGFR-containing vesicles, thus reducing EGFR degradation and enhancing EGF-induced serum response element transcription activity.
Therefore, our results indicated that SHKBP1 could promote EGFR signaling pathway by interrupting c-Cbl-CIN85 complex and inhibiting
EGFR degradation. Copyright © 2011 John Wiley & Sons, Ltd.
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INTRODUCTION
Epidermal growth factor receptor (EGFR) plays a critical
role in the regulation of many biological responses such as
cell proliferation, differentiation and cellular adhesion.1–4
Thus, the regulation of EGFR signaling is very important
to maintain tissue homeostasis.5 Aberrations in the EGFR
activity could lead to the development of various cancers
such as lung, breast and brain cancers.3,6,7 To regulate the
lifetime of this signaling, the activated EGFR also triggers
the negative feedback loop that inhibits its activation by pro-
moting its endocytosis and lysosomal degradation. Casitas
B-lineage lymphoma (Cbl) family member c-Cbl plays a
crucial role in this process, acting as an ubiquitin ligase as
well as an endocytic adaptor molecule. Upon growth factor
stimulation, c-Cbl binds to activated EGFR and acts as a
multifunctional adaptor protein to recruit additional endocy-
tic regulatory proteins such as Cbl-interacting protein of 85
kDa (CIN85), which plays important roles in receptor endo-
cytosis and degradation.7–9
Through the tyrosine kinase binding module and the ring-
finger domain in its amino terminus, c-Cbl could promote
the ubiquitination of various activated receptor tyrosine kinases
(RTKs) such as EGFR and c-Met.10 The carboxyl terminus of
c-Cbl contains a long proline-rich domain, which serves as
an adaptor for binding to multiple signaling proteins and
transducing intracellular signaling cascades.11 CIN85 is a
ubiquitously expressed adaptor protein with three SH3
domains at the amino terminus, as well as a proline-rich re-
gion and a coiled-coil domain at the carboxyl terminus.12,13
The c-Cbl-CIN85 complex is formed through the interaction
between proline–arginine motif PXXXPR (X denotes any
amino acid) of c-Cbl and SH3 domains of CIN85. The
arginine-to-alanine mutation in PXXXPR motif abolished
the formation of the c-Cbl-CIN85 complex and attenuated
the negative feedback regulation of EGFR signaling.14,15
Several recent findings indicated that EGFR signaling can
be finely tuned by regulating the functions of c-Cbl-CIN85
complex. For example, Sprouty2 has been shown to seques-
ter c-Cbl away from CIN85 and activated EGFR to inhibit
the down-regulation of EGFR signaling.16–18 Another pro-
tein named cloned-out of library 1 (Cool 1), a nucleotide ex-
change factor for Cdc42, is able to form a complex with
c-Cbl, thus preventing its interaction with activated EGFR
and reducing EGFR degradation.18 Other proteins, such as
infected cell protein 0 (ICP0) and Arf GTPase-activating
proteins ASAP1, and adaptor proteins Huntingtin-interacting
protein 1-related protein (Hip1R) and signal-transducing
adaptor protein 1 (STAP1) also are implicated in the regula-
tion of EGFR signaling.15,19
In the present study, we found SH3KBP1-binding protein
1 (SHKBP1) bound to SH3 domains of CIN85 via two
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PXXXPR motifs in its carboxyl terminus. SHKBP1 could
compete with c-Cbl to interact with CIN85 and attenuate
the down-regulation of EGFR signaling following receptor
activation. Overexpression of SHKBP1 delayed the degrada-
tion of EGFR and enhanced EGFR signaling by disturbing
the translocation of CIN85 to EGFR-containing vesicles.
Taken together, these data provide a novel mechanism of




EGF (PHG0311) was purchased from Invitrogen (Carlsbad,
CA, USA). Rabbit anti-EGFR polyclonal antibody (06–129)
and mouse anti-c-Cbl monoclonal antibody (05–440) were
purchased from Millipore (Billerica, MA, USA). Mouse
anti-FLAG monoclonal antibody (M2) (A2220) and mouse
anti-a-tubulin Clone B-5-1-2 (T5168) were purchased form
Sigma (St. Louis, MO, USA). Mouse anti-Myc monoclonal
antibody was prepared from a mouse hybridoma clone 9E10
obtained from ATCC (Manassas, VA, USA). Alexa fluor
594 goat anti-mouse IgG (H+L) (A-11005) and Alexa fluor
594 goat anti-rabbit IgG (H+L) (A-11012) were purchased
from Invitrogen (Carlsbad, CA, USA). Full length cDNA
of SHKBP1 (MMM1013-9201499) was purchased from
Open Biosystems (Huntsville, AL, USA). Full-length cDNA
of c-Cbl and CIN85 were kindly provided by Dr Biao Wang
(Department of Medicine, University of Minnesota
Medical School). EGFR/pRK5 and serum response element
(SRE)-Luc reporter plasmids were kindly provided by
Prof. Zhengjun Chen (Institute of Biochemistry and Cell
Biology, Shanghai Institutes for Biological Sciences) and
Dr Bernard Roizman (Department of Molecular Genetics
and Cell Biology, University of Chicago), respectively. Myc-
SHKBP1 and Myc-c-Cbl inserts were prepared by PCR using
the corresponding full-length cDNA plasmids as template and
cloned into the mammalian expression vector pCMV-3Tag2
(Stratagene, Santa Clara, CA, USA). Similarly, Flag-SHKBP1,
Flag-CIN85, Flag-CIN85-3SH3 and Flag-CIN85-PCC PCR
products were cloned into the pCMV-3Tag1 vector. GFP-
CIN85 was prepared by PCR using full-length CIN85 cDNA
plasmid as template and cloned in to the pEGFPC1
vector. SHKBP1-R623A and SHKBP1-R684A were obtained
by site-directed mutagenesis of wild-type SHKBP1 using the
TaKaRa MutanBEST Kit (TaKaRa, Dalian, Liaoning, China).
SHKBP1-R623A/R684A was obtained by site-directed muta-
genesis of SHKBP1-R623A using the TaKaRa MutanBEST
Kit. Sequences of all constructs were verified by sequencing,
and the primers used for construction were listed in Table S1.
Cells and transfection
HEK293T and HeLa cells were purchased from ATCC
(Manassas, VA, USA) and cultured in DMEM medium
(Invitrogen, Carlsbad, CA, USA) supplemented with 10%
fetal bovine serum (Gibco, Grand Island, NY, USA) and
1% antibiotics (Sigma, St. Louis, MO, USA) in a humidified
incubator at 37C supplied with 5% CO2. For transfection,
0.5106 cells were seeded onto individual well of six-well
plates and cultured for 24h before transfection with DNA
using LipofectAMINE reagent (Invitrogen, Carlsbad, CA,
USA) following manufacturer’s instructions. Thirty-six
hours after transfection, the cells were incubated with
serum-free DMEM medium for additional 12h and subse-
quently treated with 100ngml-1 of EGF for the time indi-
cated. After EGF treatment, the cells were washed with
cold PBS and lysed in cold lysis buffer (50mmoll-1 of 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES),
pH 74, 150mmoll-1 of NaCl, 1mmoll-1 of EDTA, 1
mmoll-1 of EGTA, 10% glycerol and 1% Triton X-100)
supplemented with a cocktail of protease and phosphatase
inhibitors as previous reported.20
Yeast two-hybrid experiment
The ProQuest yeast two-hybrid system was used to study
protein–protein interaction according to the manufacturer’s
instructions (Invitrogen, Carlsbad, CA, USA). DNA encod-
ing SHKBP1 and its mutants were cloned into the pDBLeu
vector, whereas DNA of CIN85 was cloned into the pPC86
vector. Yeast cells (MAV203 strain) were co-transformed
with the CIN85 plasmid and either a wild type or mutant
SHKBP1 plasmid to study protein–protein interaction.
SHKBP1 or its mutants co-transformed with empty pPC86
and CIN85 co-transformed with empty pDBLeu were used
as control. Meanwhile, co-transformed pPC86 and pDBLeu
vectors were used as negative control in this experiment.
After transformation, the yeasts were spread on the SC-
Leu-Trp plates (synthetic complete culture medium with
15% agar that lacks leucine and tryptophan prepared fol-
lowing the manufacturer’s instruction) and placed in a 37C
incubator for 5–7days. Visible yeast colonies were picked
up and analysed using a LacZ beta-galactosidase assay with
X-gal substrate to determine the interaction of CIN85 with
wild-type or mutant SHKBP1. The interaction was scored
and compared with the positive and negative control yeast
strains supplied by the manufacturer.
Immuno-precipitation and Western blot
Cell lysates were quantitated by Bio-Rad protein assay kit II
(Bio-Rad Laboratories, Hercules, CA, USA). Same amount
of protein from each lysate was mixed with either mouse
anti-Myc or anti-FLAG (M2) monoclonal antibody and pro-
tein A beads (GE Healthcare, Piscataway, NJ, USA) in a
microcentrifuge tube and placed on a rotator overnight at
4C. Normal mouse IgG was used as control antibody for
the immuno-precipitation. The immuno-complexes precipi-
tated with protein A beads were washing in ice-cold lysis
buffer a few times and finally resuspended and boiled
in Uli Laemmli sample buffer. The immuno-precipitates
were resolved using sodium dodecyl sulfate PAGE, trans-
ferred to Polyvinylidene Fluoride (PVDF) membranes and
probed with the indicated primary antibodies as previously
reported.21
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Immuno-fluorescence
To study the co-localization of SHKBP1 or its mutants with
CIN85, HEK293T cells seeded on collagen-coated cover
slips were transfected with indicated expression plasmids
for 36h and starved for additional 12h. Transfected cells
were then stimulated with or without EGF (100ngml-1)
for 10min and then fixed in 4% formaldehyde for 20min.
After permeabilization and blocking, the cells were incu-
bated with primary antibodies and then with Alexa Fluor-
conjugated secondary antibodies (Invitrogen, Carlsbad,
CA, USA). The preparations were mounted, and the images
were taken with a confocal microscope (Carl Zeiss, Jena,
Germany).
Luciferase reporter assay
HEK293T or HeLa cells were seeded and cultured in collagen-
coated 12-well plates overnight. The cells were transfected
with the indicated plasmids, together with SRE-Luc and
beta-galactosidase reporter plasmids. Thirty-sixhours
post-transfection, the cells were incubated with serum-free
DMEM for an additional 12h and then stimulated with 100
ngml-1 EGF for the indicated time. Stimulated cells were
lysed in 1 lysis buffer, and the lysates were mixed with
luciferase assay reagent according to the manufacturer’s
instructions (Promega, Madison, MI, USA). After incuba-
tion in the dark for the indicated time, the luciferase activ-
ity was measured by a Victor Wallace luminometer (Turku,
Finland), and the luciferase activity was normalized
against beta-galactosidase activity measured in parallel.22
The samples were prepared in triplicates and measured,
and the normalized luciferase activity was expressed as the
meanSD.
RESULTS
PXXXPR motifs of SHKBP1 constitutively bound to CIN85
CIN85 was found to bind to proline–arginine motif
PXXXPR contained in numerous adaptor proteins including
c-Cbl, Cbl-b, Sprouty2, Cool1, ASAP1 and STAP1.2,15,17,18
Through bioinformatic analysis, we found that SHKBP1
had two PXXXPR motifs in the carboxyl terminus: PSPSPR
(aa: 618–623) and PTPAPR (aa: 679–684), indicating
potential interaction with CIN85. Indeed, yeast two-hybrid
experiments confirmed the interaction of SHKBP1 with
CIN85 (Table 1). The arginine residue within the proline–
arginine motif has been shown to be essential for the inter-
action with SH3 domain, as the arginine-to-alanine mutation
abolished this association.17 To explore the role of two
PXXXPR motifs in the interaction of SHKBP1 with
CIN85, arginine residues in these two motifs were mutated
to alanine residues. Three SHKBP1 mutants—SHKBP1-
R623A (denoted as R623A), SHKBP1-R684A (denoted as
R684A) and SHKPB1-R623A/R684A (denoted as R623A/
R684A)—were created and tested in the yeast two-hybrid
interaction assay. Yeast colonies with R623A plasmid
showed a strong positive signal, whereas colonies containing
R684A plasmids only showed a weak positive signal in
the LacZ assay (Table 1). In addition, colonies with the
double mutant R623A/R684A plasmid showed no signal
at all (Table 1). Taken together, these findings indicated
that two PXXXPR motifs are responsible for the inter-
action of SHKBP1 with CIN85, although the contribu-
tion of the two motifs to the interaction seemed to be
different.
To confirm that this interaction also occurs in mammalian
cells, SHKBP1-expressing plasmid was co-transfected with
CIN85-coding vector into HEK293T cells. Co-immuno-
precipitation study demonstrated the interaction between
SHKBP1 and CIN85 in the transfected cells (Figure 1a). Fur-
thermore, SH3 domains (CIN85-3SH3) but not the proline-
rich region and coiled-coil region (CIN85-PCC) contributed
to the binding of CIN85 to SHKBP1 (Figure 1b). Although
single mutants R623A and R684A could bind to CIN85, the
double mutant R623A/R684A failed to interact with CIN85
(Figure 1c). Interestingly, we found that the interaction of
SHKBP1 with CIN85 was not affected by EGF stimulation
(Figure 1c). The above data suggested a direct and constitu-
tive interaction between SHKBP1 and CIN85, which was
mediated by PXXXPR motifs of SHKBP1.
SHKBP1 competed with c-Cbl to bind to CIN85 through its
two PXXXPR motifs
It was known that c-Cbl associated with CIN85 through the
PXXXPR motif of c-Cbl and the SH3 domain(s) of CIN85,
and EGF stimulation could further promote the assembly of
Table 1. Yeast two-hybrid experiment examining the interaction of SHKBP1 or its mutants with CIN85
Plasmids
SHKBP1 SHKBP1-R623A SHKBP1-R684A SHKBP1-R623A/684A pDBLeu
CIN85 CIN85 CIN85 CIN85 pPC86
LacZ activity +++ +++ + - -
Plasmids SHKBP1
pPC86
SHKBP1-R623A SHKBP1-R684A SHKBP1- R623A/684A pDBLeu
pPC86 pPC86 pPC86 CIN85
LacZ activity - - - - -
MAV203 yeast strain was co-transformed with SHKBP1/pDBLeu or its mutants plasmids and CIN85/pPC86 plasmids. SHKBP1 or its mutants co-transformed
with empty pPC86 and CIN85 co-transformed with empty pDBLeu were used as control. pPC86 and pDBLeu vectors were used as negative control. Trans-
formed yeasts were selected in SC-Leu-Trp plates, and a LacZ assay was performed with colonies grown on the SC-Leu-Trp plates and control yeast strains: a
strong positive control A, a weak positive control C and a negative control supplied by manufacturer. (‘+++’ indicates a strong positive signal, ‘+’ indicates a
weak positive signal and ‘–’ indicates a negative signal).
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this complex.4,9 The dependence of the SHKBP1-CIN85
interaction on PXXXPR motifs of SHKBP1 led us to as-
sume whether SHKBP1 could interfere with the association
between c-Cbl and CIN85. As previously reported, c-Cbl
could bind to CIN85 (Figure 2a). However, such an associ-
ation was completely abolished in the presence of ectopically
Figure 1. PXXXPR motifs of SHKBP1 constitutively bound to CIN85. (a) HEK293T cells co-transfected with Myc-SHKBP1 and Flag-CIN85 plasmids
were lysed 48h after transfection. Immuno-precipitations were performed with anti-Myc antibody and control mouse IgG (mIgG). Immuno-precipitated pro-
teins were processed for Western blot with anti-FLAG antibody. The membrane was stripped and re-blotted with anti-Myc antibody. (b) HEK293T cells
co-transfected with Flag-CIN85-3SH3 or Flag-CIN85-PCC and Myc-SHKBP1 plasmids were lysed 48h after transfection, and cell lysates were immuno-
precipitated with anti-FLAG antibody and control mIgG. Immuno-precipitated proteins were processed for Western blot with anti-Myc antibody. The membrane
was stripped and re-blotted with anti-FLAG antibody. (c) HEK293T cells transfected with Myc-SHKBP1 or its mutants and Flag-CIN85 plasmids were starved in
serum-free DMEM for 12h and then treated with 100ngml-1 of recombinant human EGF for 10min. The cells were lysed and immuno-precipitated with anti-
Myc antibody. Immuno-precipitated proteins were processed for Western blot with anti-FLAG antibody, and the membrane was then stripped and re-blotted
with anti-Myc antibody
Figure 2. SHKBP1 competed with c-Cbl to bind to CIN85 through its two PXXXPR motifs. (a) HEK293T cells co-transfected with expression plasmids
encoding Myc-c-Cbl, Flag-SHKBP1 or Flag-CIN85 were lysed 48h after transfection, and cell lysates were immuno-precipitated with anti-Myc antibody and
control mIgG. Immuno-precipitated proteins were processed for Western blot with anti-FLAG antibody, and the membrane was stripped and re-blotted with
anti-Myc antibody. (b) HEK293T cells co-transfected with plasmids encoding Myc-c-Cbl, Myc-SHKBP1 and Flag-CIN85 were lysed 48h after transfection,
and cell lysates were immuno-precipitated with anti-FLAG antibody and control mIgG. Immuno-precipitated proteins were processed for Western blot with
anti-Myc antibody, and the membrane was stripped and re-blotted with anti-FLAG antibody. (c) HEK293T cells co-transfected with plasmids encoding
Myc-c-Cbl, Myc-R623A/684A and Flag-CIN85 were lysed 48h after transfection, and cell lysates were immuno-precipitated with anti-FLAG antibody and
control mIgG. Immuno-precipitated proteins were processed for Western blot with anti-Myc antibody, and the membrane was stripped and re-blotted with
anti-FLAG antibody
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expressed SHKBP1 (Figure 2a). c-Cbl did not bind to
SHKBP1 and failed to affect the association of SHKBP1
and CIN85 in co-transfected cells (Figures 2a and 2b). Im-
portantly, the double mutant R623A/R684A failed to affect
the interaction between c-Cbl and CIN85 (Figure 2c). These
data indicated that SHKBP1 interfered with the formation
of the c-Cbl-CIN85 complex through sequestration of
CIN85 via its two PXXXPR motifs.
SHKBP1 inhibited EGFR degradation after
EGF stimulation
Next, we hypothesized that the direct binding of SHKBP1 to
CIN85 could attenuate c-Cbl-CIN85 complex promoted
EGFR degradation.4 To test it, the EGFR level in the trans-
fected cells was measured following EGF stimulation of
cells transected with wild-type or various mutants of
SHKBP1. As shown in Figure 3a, the EGFR level was up-
regulated immediately upon EGF stimulation and then
reduced gradually. The EGFR protein was not detectable
about 180min after EGF stimulation in mock vector trans-
fected cells (Figure 3a). Overexpression of wild-type
SHKBP1 and R623A mutant strongly delayed the degra-
dation of EGFR upon EGF activation (Figures 3b and 3c).
In contrast, the receptor degradation was only slightly delayed
by the overexpression of R684A mutant (Figure 3d), whereas
the R623A/R684A double mutant showed no effect at all
(Figure 3e).
The expression level of SHKBP1 and its various mutants
in transfected cells remained the same during the time
course of EGF stimulation (Figures 3a–3e). In contrast,
quantitative analysis of relative EGFR levels in these cells
clearly demonstrated changes in EGFR expression (Figure 3f).
These data suggested that SHKBP1 interfered with the for-
mation of c-Cbl-CIN85 complex by its binding to CIN85,
thereby retarding c-Cbl-CIN85-dependent EGFR degrad-
ation after EGF stimulation.
SHKBP1 disturbed the translocation of CIN85 to
EGFR-containing vesicles
CIN85 was found to co-localize with EGFR and c-Cbl com-
plex upon EGF stimulation, which is important to receptor
endocytosis and the formation of EGFR-containing vesicles
during EGFR degradation.8,23 We therefore explored the
localization of SHKBP1 and its role on CIN85 translocation
after EGF stimulation by immuno-fluorescence. CIN85
translocated to EGFR-containing vesicles upon EGF stimu-
lation (Figures 4a and 4d). Overexpression of wild-type
SHKBP1 and single mutant R623A and R684A inhibited
the formation of EGFR-containing vesicles and the trans-
location of CIN85 (Figures 4b, 4e and Figure S1). In con-
trast, the expression of double mutant R623A/R684A did
not disturb the translocation of CIN85 to EGFR-containing
vesicles (Figures 4c and 4f). These data suggested that
SHKBP1 could disturb the translocation of CIN85 to
Figure 3. SHKBP1 inhibited EGFR degradation after EGF stimulation. HeLa cells were transfected with indicated expression plasmids: pCMV (a), Myc-
SHKBP1 (b), Myc-R623A (c), Myc-R684A (d) and Myc-R623A/684A (e), respectively. Thirty-sixhours post-transfection, cells were starved in serum-free
DMEM for 12h. The cells were then stimulated with 100ngml-1 of EGF for the indicated times. Lysates were prepared and analysed using Western blot with
anti-EGFR, anti-Myc or anti-a-tubulin antibodies. The relative level of EGFR (a–e) was quantified using densitometry scan and graphed in (f)
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EGFR-containing vesicles upon EGF stimulation via the
interaction of its PXXXPR motifs with CIN85.
SHKBP1 enhanced EGF-induced SRE transcription activity
Finally, we examined whether the reduction in EGFR deg-
radation caused by overexpression of SHKBP1 would lead
to the alteration in the downstream signaling. It was known
that activated EGFR can induce transcription activity of pro-
moters with the SRE.19 Therefore, the SRE luciferase re-
porter assay was used to examine the effect of SHKBP1
on EGFR signaling. Different amounts of SHKBP1 were
co-transfected with the SRE-Luc gene reporter, c-Cbl,
CIN85 and EGFR into HEK293T cells, and the luciferase
Figure 4. SHKBP1 disturbed the translocation of CIN85 to EGFR degradation vesicles. HEK293T cells were co-transfected with GFP-CIN85 plasmid
and control pCMV mock vector (a, d), Myc-SHKBP1 (b, e) or Myc-R623A/R684A (c, f). Thirty-sixhours post-transfection, cells were starved in serum-free
DMEM for 12h. The cells were left unstimulated or stimulated with hEGF for 10min. Immuno-fluorescence studies on cells were performed with antibodies
against Myc tag (a, b, c) or EGFR (d, e, f), and the nucleus was stained with DAPI. The merged pictures were shown in the bottom panel, and the staff (10mm)
was shown in the upper panel
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activities in transfected cells were measured. The luciferase
activities showed a dose-dependent effect of SHKBP1 on
SRE transcription (Figure S2). Moreover, overexpression
of SHKBP1, R623A or R684A mutant could signifi-
cantly increase the SRE transcription activity by threefold
(P=0001), 25-fold (P=0003) and 26-fold (P=0002),
when compared with the mock vector group, respectively
(Figure 5a). Similarly, overexpression of SHKBP1, R623A
or R684A mutants in HeLa cells could increase the
SRE transcription activity by 22 fold (P=0003), 17 fold
(P=0036) and 20 fold (P=0001), respectively (Figure 5b).
However, R623A/R684A double mutant had little effect on
SRE-Luc reporter transcription in both HEK293T and HeLa
cells, indicating that SHKBP1 could enhance EGFR signal-
ing through its interaction with CIN85.
DISCUSSION
In the current study, we found that SHKBP1 could bind to
SH3 domains of CIN85 through its PXXXPR motifs in the
carboxyl terminus (Figure 1 and Table 1). We further
showed that the interaction of SHKBP1 with CIN85 could
abolish c-Cbl-CIN85 complex formation (Figure 2), thus
retarding EGFR degradation by disturbing the translocation
of CIN85 to EGFR-containing vesicles following EGF
stimulation (Figures 3 and 4 and Figure S1). Consistent with
these observations, SHKBP1-enhanced EGFR signaling
induced the SRE transcriptional reporter activity, which
required at least one intact PXXXPR motif (Figure 5 and
Figure S2).
The binding of EGF to EGFR induces receptor activation
and downstream signaling cascades important to cell prolif-
eration, differentiation and migration.1,2,4 Aberrant activa-
tion or overexpression of EGFR is commonly found in
various cancers. It is clear that proper regulation of EGFR
signaling is essential for normal physiology.1,6 The c-Cbl-
CIN85 complex has been shown to play a critical role in
the down-regulation of activated EGFR. c-Cbl is associated
with the cytoplasmic domain of EGFR upon receptor activa-
tion and catalyses the ubiquitination of EGFR.7 c-Cbl acts as
a multifunctional adaptor protein to recruit CIN85 to the
EGFR-c-Cbl complex, which facilitates the endocytosis of
ubiquitinated EGFR and subsequent degradation. Therefore,
the perturbation of EGFR-c-Cbl-CIN85 complex could have
severe consequences in EGFR-regulated cell growth con-
trol. This regulatory mechanism has been reported for many
c-Cbl-associated proteins. For example, Sprouty2 not only
acts at the interface of the c-Cbl-CIN85 complex but also
directly associates with c-Cbl to sequester c-Cbl from acti-
vated EGFR, thus inhibiting the down-regulation of EGFR
signaling.16,17 Additionally, Cool-1, a nucleotide exchange
factor for Cdc42, is able to form a complex with c-Cbl,
thereby sequestering c-Cbl from activated EGFR and pre-
venting the down-regulation of EGFR signaling.18
We found SHKBP1 as a new regulator in EGFR activa-
tion. Unlike Sprouty2 and Cool-1 that promote EGFR sig-
naling through their interaction with c-Cbl, SHKBP1 could
retard EGFR degradation and up-regulate EGFR signaling
by binding to CIN85 and sequestering CIN85 from c-Cbl-
CIN85 complex. PXXXPR motifs were essential for this
function of SHKBP1. Therefore, our results may reveal a
new mechanism of enhanced EGFR signaling in the devel-
opment of various diseases such as cancers. It would be
interesting to investigate whether the interaction of
SHKBP1 with CIN85 also is involved in the regulation of
other RTKs during cancer development.
In summary, our study demonstrated that SHKBP1 inhib-
ited c-Cbl-CIN85 complex-mediated down-regulation of
EGFR signaling by sequestration of CIN85. This novel
mechanism provides an alternative route for the develop-
ment of drugs targeting the EGFR signaling pathway.
Figure 5. SHKBP1 enhanced EGF-induced SRE transcription activ-
ity. (a) HEK293T cells were co-transfected with EGFR (100ng), c-Cbl
(100ng), CIN85 (100ng), SRE-Luc (100ng), b-gal (50ng) and SHKBP1
or its mutants plasmids (300ng). Thirty-sixhours post-transfection, cells
were starved in serum-free DMEM for 12h. The cells were then stimulated
with EGF for another 12h and processed for luciferase assay. (b) HeLa cells
were co-transfected with SRE-Luc (200ng), b-gal (100ng) and SHKBP1 or
its mutants plasmids (300ng). Thirty-sixhours post-transfection, cells were
starved in serum-free DMEM for 12h. The cells were then stimulated with
EGF for additional 12h and processed for luciferase assay. The luciferase
activity was measured in triplicated samples and expressed as the mean
SD. Student’s t-test was performed to compare the statistical difference be-
tween each group to pCMV control group. *P<005; **P<001
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